ISPOR - What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?

Full Text

What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?

Abstract

Authors

M. Ascano T. Stewart B. Perez-Cheeks D. Holman R. Moore M. Tomich

Back to Volume 18, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now